These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3479296)

  • 1. Relative bioavailability of ofloxacin tablets in comparison to oral solution.
    Malerczyk V; Verho M; Korn A; Rangoonwala R
    Curr Med Res Opin; 1987; 10(8):514-20. PubMed ID: 3479296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Pharmatherapeutica; 1985; 4(6):376-82. PubMed ID: 3866256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of food on the pharmacokinetics of ofloxacin.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Curr Med Res Opin; 1986; 10(3):166-71. PubMed ID: 3460737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioavailability of ofloxacin from several formulations.
    Flor S; Beals B
    Curr Med Res Opin; 1991; 12(5):282-6. PubMed ID: 2004540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
    Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and relative bioavailability of ofloxacin tablets in 12 healthy volunteers.
    Diao Y; Li L; Zhou GH; Cheng Y
    Zhongguo Yao Li Xue Bao; 1992 Mar; 13(2):110-2. PubMed ID: 1598824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man.
    Verho M; Malerczyk V; Damm D; Lehr KH
    Drug Metabol Drug Interact; 1996; 13(1):57-67. PubMed ID: 8902431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers.
    Agarwal S; Solomon WD; Gowda KV; Selvan PS; Ghosh D; Sarkar AK; Chattaraj TK; Pal TK
    Arzneimittelforschung; 2007; 57(10):679-83. PubMed ID: 18074762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and pharmacokinetics of oral ofloxacin formulations in normal subjects.
    Stein GE; LeBel M; Flor SC; Zinny M
    Curr Med Res Opin; 1991; 12(8):479-84. PubMed ID: 1764952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose related pharmacokinetics of ofloxacin in healthy volunteers.
    Immanuel C; Hemanthkumar AK; Gurumurthy P; Venkatesan P
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1017-22. PubMed ID: 12475149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
    Vincent J; Teng R; Pelletier SM; Willavize SA; Friedman HL
    Am J Surg; 1998 Dec; 176(6A Suppl):23S-26S. PubMed ID: 9935253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals].
    Minami S; Takahata M; Hayashi T; Kumano K; Ikeda Y; Noumi T; Takagi S; Oogake N; Tsuneda R; Maehana J
    Jpn J Antibiot; 1995 May; 48(5):626-42. PubMed ID: 7637197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.
    Verho M; Korn A; Badian M; Malerczyk V; Waldhäusl W
    Chemotherapy; 1988; 34(3):170-7. PubMed ID: 3166420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers.
    Leggio GM; Incognito T; Privitera G; Marano MR; Drago F
    J Endocrinol Invest; 2006 Dec; 29(11):RC35-8. PubMed ID: 17259789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transfer of ofloxacin into suction blister fluid after its oral administration].
    Aoyama H; Sugiyama H; Ishii T; Kawauchi T; Kasuya T; Nishizaki A; Okuda J
    Jpn J Antibiot; 1987 Nov; 40(11):1937-40. PubMed ID: 3481837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ofloxacin after parenteral and oral administration.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1338-42. PubMed ID: 3479046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
    Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
    Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.